Autem Therapeutics Raises $10 Million Series A-1 Financing For Novel Bioelectric Cancer Treatment Platform
Autem Therapeutics Raises $10 Million Series A-1 Financing For Novel Bioelectric Cancer Treatment Platform
06/06/22, 5:11 PM
Location
hanoverMoney raised
$10 million
Round Type
series a
Autem Therapeutics LLC (“Autem Therapeutics” or “the Company”), an emerging oncology therapeutic and bioelectric technology company, has announced the completion of its $10 million Series A-1 financing round. The round was led by Zentynel Frontier Investments with other new and existing investors participating.
Company Info
Location
hanover, new hampshire, united states
Additional Info
The company also announced the appointment of Michael Choukas as Chief Executive Officer. The company has received FDA breakthrough designation for the treatment of advanced HCC (liver cancer) patients. ABOUT AUTEM THERAPEUTICS Autem Therapeutics is a privately held oncology therapeutic and bioelectric company headquartered in Hanover NH, USA that is developing a novel, non-invasive and non-toxic oncology treatment platform targeting HCC (liver cancer) and other solid tumor cancers. The company has received FDA breakthrough designation for its AutEMsys™ therapy for the treatment of advanced HCC patients. Autem Therapeutics is developing a novel bioelectric oncology treatment platform targeting Hepatocellular Carcinoma (HCC) and other solid tumor cancers.